NCT02424305View on ClinicalTrials.gov

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Actinic Keratosis
Interventions
DRUG

LEO 43204 gel 0.018%

DRUG

LEO 43204 gel 0.1%

DRUG

LEO 43204 gel 0.037%

Trial Locations (1)

7866

Pflugerville Dermatology Clinical Research, Pflugerville

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY

NCT02424305 - Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions | Biotech Hunter | Biotech Hunter